NA

Nasus Pharma Ltd

  • CIK: 0002029039
  • EIN: 51-6022712
  • Business address: 29 HARAKEVET ST, TEL AVIV - YAFO, Israel, 6618003

Information

  • Mailing address
    29 HARAKEVET ST, TEL AVIV - YAFO, Israel, 6618003
  • Phone
    972 54-255-3956
  • State location
    Israel
  • State of incorporation
    Israel
  • Fiscal year end
    December 31
  • SIC
    2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS
  • Filings
    N/A

About Nasus Pharma Ltd

Nasus Pharma Ltd (CIK: 0002029039) is an American company incorporated in the state of Israel. Head office is located at 29 HARAKEVET ST, TEL AVIV - YAFO, Israel, 6618003. Work in the industry 2834 - (CF Office: Office of Life Sciences) PHARMACEUTICAL PREPARATIONS. Nasus Pharma Ltd is a public company and trade via Over-The-Counter (OTC).

Ownership

Updating!

Stock Chart

Coming soon!

Jobs

Coming soon!

Recent SEC Filings

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Nasus Pharma Ltd

Filings Format Description Filed/Effective File/Film Number
6-K Document

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Acc-no: 0001493152-25-017378 (34 Act) Size: KB		 Oct-08-2025

001-42796

251381317
6-K Document

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Acc-no: 0001493152-25-016290 (34 Act) Size: KB		 Sep-30-2025

001-42796

251360421
6-K Document

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Acc-no: 0001493152-25-012675 (34 Act) Size: KB		 Sep-05-2025

001-42796

251295025
SCHEDULE 13G Document Acc-no: 0001178913-25-003007 (34 Act) Size: KB Aug-20-2025

005-95201

251237500
6-K Document

Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments

Acc-no: 0001493152-25-011984 (34 Act) Size: KB		 Aug-14-2025

001-42796

251219260
424B4 Document

Prospectus filed pursuant to Rule 424(b)(4)

Acc-no: 0001641172-25-023826 (33 Act) Size: KB		 Aug-14-2025

333-288582

251216629
EFFECT Document Acc-no: 9999999995-25-002578 (33 Act) Size: KB Aug-12-2025

333-288582

251208753
CERT Document Acc-no: 0001143313-25-000055 (34 Act) Size: KB Aug-12-2025

001-42796

251207446
8-A12B Document

Form for the registration / listing of a class of securities on a national securities exchange pursuant to section 12(b)

Acc-no: 0001493152-25-011753 (34 Act) Size: KB		 Aug-08-2025

001-42796

251198595
F-1/A Document

Amendment to Registration statement for securities of certain foreign private issuers

Acc-no: 0001493152-25-011714 (33 Act) Size: KB		 Aug-07-2025

333-288582

251195480
FWP Document

Filing under Securities Act Rules 163/433 of free writing prospectuses

Acc-no: 0001493152-25-011504 (34 Act) Size: KB		 Jul-30-2025

333-288582

251167728
FWP Document

Filing under Securities Act Rules 163/433 of free writing prospectuses

Acc-no: 0001493152-25-011447 (34 Act) Size: KB		 Jul-28-2025

333-288582

251153581
F-1/A Document

Amendment to Registration statement for securities of certain foreign private issuers

Acc-no: 0001493152-25-011444 (33 Act) Size: KB		 Jul-28-2025

333-288582

251153527
F-1 Document

Registration statement for securities of certain foreign private issuers

Acc-no: 0001641172-25-018388 (33 Act) Size: KB		 Jul-09-2025

333-288582

251113550
DRS/A Document Acc-no: 0001641172-25-011885 (33 Act) Size: KB May-21-2025

377-07416

25972355
DRS/A Document Acc-no: 0001641172-25-009584 (33 Act) Size: KB May-12-2025

377-07416

25933062
DRS/A Document Acc-no: 0001641172-25-006692 (33 Act) Size: KB Apr-29-2025

377-07416

25889244
DRS/A Document Acc-no: 0001641172-25-005110 (33 Act) Size: KB Apr-16-2025

377-07416

25843609
DRS/A Document Acc-no: 0001641172-25-000173 (33 Act) Size: KB Mar-21-2025

377-07416

25761636
DRS/A Document Acc-no: 0001493152-25-005072 (33 Act) Size: KB Feb-06-2025

377-07416

25595173

Recent 20 filings. View all Nasus Pharma Ltd filings

Reviews

Overall rating 5.0

Aug 22, 2022

Ryan Storey

Huge help thank you for your help .. y'all make it so much easier

Aug 22, 2022

Samuel Ejimofor

It's being easier working on the website. And I recommend, it's a great website

Aug 22, 2022

Jean Bishop

Very good communication and delivery made within the timeframe I was advised of

Frequently Asked Questions

Tags:

  • Nasus Pharma Ltd overview
  • Nasus Pharma Ltd job
  • Nasus Pharma Ltd stock
  • Nasus Pharma Ltd ownership
  • Nasus Pharma Ltd CEO
  • Nasus Pharma Ltd documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.

Orther Companies

atai Life Sciences Luxembourg S.A.
Update: Sep 23, 2025
Hyperliquid Strategies Inc
Update: Sep 05, 2025
Polaryx Therapeutics, Inc.
Update: Sep 05, 2025
Promicell, Inc.
Update: May 30, 2025
Maius Pharmaceutical Group Co., Ltd.
Update: Mar 01, 2025
Sionna Therapeutics, Inc.
Update: Jan 18, 2025

Latest News

SEC Adopts Rules to Improve Clearing Agency Governance and Mitigate Conflicts of Interest
SEC Adopts Rules to Improve Clearing Agency Governance and Mitigate...
SEC Press Releases  Nov 17, 2023 4433 Views
Charter Communications to Pay $25 Million Penalty for Unauthorized Stock Buybacks
Charter Communications to Pay $25 Million Penalty for Unauthorized...
SEC Press Releases  Nov 15, 2023 1653 Views
SEC Announces Enforcement Results for Fiscal Year 2023
SEC Announces Enforcement Results for Fiscal Year 2023
SEC Press Releases  Nov 15, 2023 2592 Views
SEC Charges Former Co-CEOs of Tech Start-Up Bitwise Industries for Falsifying Documents While Raising $70 Million From Investors
SEC Charges Former Co-CEOs of Tech Start-Up Bitwise Industries...
SEC Press Releases  Nov 10, 2023 3667 Views
SEC Charges Royal Bank of Canada with Internal Accounting Controls Violations
SEC Charges Royal Bank of Canada with Internal Accounting Controls...
SEC Press Releases  Nov 03, 2023 3755 Views
SEC Charges President/CCO of Prophecy Asset Management Advisory Firm with Multi-Year Fraud
SEC Charges President/CCO of Prophecy Asset Management Advisory...
SEC Press Releases  Nov 03, 2023 4925 Views
SEC Adopts Rules for the Registration and Regulation of Security-Based Swap Execution Facilities
SEC Adopts Rules for the Registration and Regulation of Security-Based...
SEC Press Releases  Nov 02, 2023 2255 Views
SEC Charges Crypto Company SafeMoon and its Executive Team for Fraud and Unregistered Offering of Crypto Securities
SEC Charges Crypto Company SafeMoon and its Executive Team for...
SEC Press Releases  Nov 01, 2023 2659 Views
SEC Charges Four Long Island Men with Perpetrating $2 Million “Free-Riding” Scheme
SEC Charges Four Long Island Men with Perpetrating $2 Million...
SEC Press Releases  Nov 01, 2023 3308 Views

© 2022 CompaniesBIO.Com. All rights reserved. Operated by